Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALPL-VYGR-NeuroShuttle
- Development stage
- Unknown
- Lead developer
- Voyager Therapeutics
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
ALPL-VYGR-NeuroShuttle is a discovery-stage, non-viral delivery platform and gene therapy candidate being developed by Voyager Therapeutics. The platform utilizes a receptor-mediated shuttle system that targets the alkaline phosphatase (ALPL) receptor to facilitate the transport of therapeutic payloads across the blood-brain barrier (BBB) into the central nervous system (CNS). Preclinical murine studies have demonstrated that the ALPL-VYGR-NeuroShuttle can maintain CNS exposure for over three weeks, significantly outperforming traditional transferrin receptor-based shuttles. While the program is currently categorized as a gene therapy in the company's pipeline, the platform is designed to be modular, capable of delivering various modalities including antibodies. The specific therapeutic target and the neurological disease indication for this program are currently undisclosed.
- Other names
- ALPL + VYGR + NeuroShuttle-Voyager Therapeutics-ALPL-gene therapy-Undisclosed
02
Targets
ALPL (Tissue-nonspecific alkaline phosphatase)
Beyond the preview
Go deeper on ALPL-VYGR-NeuroShuttle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALPL-VYGR-NeuroShuttle.